Drug Trial Radar · NCT01275066
A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)
Last checked: Nov 20, 2026Latest source record: Jul 7, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
177
Actual
Start
Feb 2011
Primary completion
Aug 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Jan 12, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3 study will evaluate the efficacy and safety of 2.0 mg/kg/week BMN 110 and 2.0 mg/kg/every other week BMN 110 in patients with mucopolysaccharidosis IVA (Morquio A Syndrome). There is currently no standard accepted treatment for MPS IVA other than supportive care. Enzyme replacement therapy (ERT) may be a potential new treatment option for MPS IVA patients. BMN 110 is administered to MPS IVA patients by IV infusion, allowing cellular uptake by the mannose-6-phosphate receptor and transportation to the lysosomes. This enzyme uptake into the lysosomes is hypothesized to promote increased catabolism of keratan sulfate (KS) in tissue macrophages, hyaline cartilage, other connective tissues, and heart valve, and reduce the progressive accumulation of KS which is responsible for the clinical manifestations of the disorders.
Conditions
- MPS IV A
Interventions
BMN 110 WeeklyDrug
BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
PlaceboDrug
Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
BMN 110 Every Other WeekDrug
BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Endurance as Measured by the 6-minute Walk TestTime frame: Baseline to Week 24
Locations
28 sites in 17 countries. Site status is shown where the registry gives one.
Site not named
Oakland, California
Site not named
Wilmington, Delaware
Site not named
Washington D.C., District of Columbia
Site not named
Chicago, Illinois
Site not named
New York, New York
Site not named
Seattle, Washington
Site not named
Córdoba, Argentina
Site not named
Campina Grande, Brazil
Site not named
Porto Alegre, Brazil
Site not named
Montreal, Canada
Site not named
Sherbrooke, Canada
Site not named
Toronto, Canada
Site not named
Bogotá, Colombia
Site not named
Copenhagen, Denmark
Site not named
Lyon, France
Site not named
Paris, France
Site not named
Mainz, Germany
Site not named
Monza, Italy
Site not named
Tokyo, Japan
Site not named
Amsterdam, Netherlands
Site not named
Coimbra, Portugal
Site not named
Doha, Qatar
Site not named
Riyadh, Saudi Arabia
Site not named
Seoul, South Korea
Site not named
Taipei, Taiwan
Site not named
Birmingham, United Kingdom
Site not named
London, United Kingdom
Site not named
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.